VIDEO: Biosimilars, Interchangeability, and Perceptions of Safety
by Ha Kung Wong
November 6, 2017
Watch Ha Kung Wong, Molly Burich, and Angus Worthing discuss interchangeability as biosimilars enter the rheumatology market in the United States, and remark on perceptions of efficacy and safety of an interchangeable biosimilar versus a biosimilar, as part of the The Center for Biosimilars™ Peer Exchange®.
Ha Kung Wong
has extensive experience litigating a wide variety of pharmaceutical cases, including those concerning biologics used to treat rheumatoid arthritis and autoimmune disorders. He also has extensive experience consulting, conducting due diligence and licensing pharmaceutical portfolios. Ha Kung has a B.S. in Biochemistry and a B.S. in Chemistry.